Centre Asset Management LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Centre Asset Management LLC bought a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 75,803 shares of the specialty pharmaceutical company’s stock, valued at approximately $9,335,000. Jazz Pharmaceuticals accounts for approximately 2.1% of Centre Asset Management LLC’s portfolio, making the stock its 21st biggest holding. Centre Asset Management LLC owned 0.13% of Jazz Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently made changes to their positions in JAZZ. GAMMA Investing LLC boosted its position in Jazz Pharmaceuticals by 49.8% during the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock worth $76,000 after purchasing an additional 206 shares in the last quarter. Versant Capital Management Inc raised its stake in shares of Jazz Pharmaceuticals by 56.7% during the 4th quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock worth $119,000 after buying an additional 350 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Jazz Pharmaceuticals by 4.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after buying an additional 48,708 shares in the last quarter. Synovus Financial Corp grew its stake in Jazz Pharmaceuticals by 2.4% in the 3rd quarter. Synovus Financial Corp now owns 19,106 shares of the specialty pharmaceutical company’s stock valued at $2,129,000 after acquiring an additional 451 shares during the last quarter. Finally, Sanctuary Advisors LLC increased its holdings in Jazz Pharmaceuticals by 502.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 11,754 shares of the specialty pharmaceutical company’s stock valued at $1,310,000 after acquiring an additional 9,804 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Down 1.6 %

Jazz Pharmaceuticals stock traded down $1.96 during midday trading on Friday, hitting $121.80. 59,065 shares of the company were exchanged, compared to its average volume of 228,927. The company has a market cap of $7.36 billion, a PE ratio of 17.15, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17. The company’s fifty day moving average price is $120.81 and its 200-day moving average price is $113.63. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the sale, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at approximately $51,742,619.25. This represents a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,753 shares of company stock worth $816,289 over the last 90 days. Company insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Robert W. Baird upped their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Needham & Company LLC reiterated a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Cantor Fitzgerald restated an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Finally, TD Cowen cut their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.